Vir Biotechnology (VIR) Projected to Post Earnings on Monday

Vir Biotechnology (NASDAQ:VIR) is expected to announce its Q4 2025 results after the market closes on Monday, February 23rd. Analysts expect the company to announce earnings of ($0.42) per share and revenue of $19.9050 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Monday, February 23, 2026 at 5:30 PM ET.

Vir Biotechnology Stock Down 3.1%

Shares of VIR stock opened at $7.47 on Monday. The business has a 50-day moving average price of $6.63 and a two-hundred day moving average price of $5.84. Vir Biotechnology has a 12-month low of $4.16 and a 12-month high of $10.01. The firm has a market cap of $1.04 billion, a P/E ratio of -2.07 and a beta of 1.69.

Analysts Set New Price Targets

Several brokerages have issued reports on VIR. Barclays reaffirmed an “overweight” rating and issued a $24.00 target price on shares of Vir Biotechnology in a research note on Wednesday, February 4th. Needham & Company LLC reiterated a “buy” rating and issued a $14.00 target price on shares of Vir Biotechnology in a research report on Monday, February 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Monday, December 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Vir Biotechnology in a research note on Tuesday, December 30th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Vir Biotechnology currently has a consensus rating of “Moderate Buy” and an average target price of $16.00.

Insider Transactions at Vir Biotechnology

In related news, Director Vicki L. Sato sold 22,000 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $7.71, for a total transaction of $169,620.00. Following the completion of the transaction, the director owned 1,144,391 shares in the company, valued at $8,823,254.61. This represents a 1.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Endurance (Cayman) Ltd Svf sold 235,971 shares of Vir Biotechnology stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $6.38, for a total transaction of $1,505,494.98. Following the completion of the sale, the insider owned 14,110,209 shares in the company, valued at approximately $90,023,133.42. This trade represents a 1.64% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 911,059 shares of company stock worth $5,699,389. 16.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On Vir Biotechnology

Large investors have recently modified their holdings of the stock. GSK plc purchased a new stake in Vir Biotechnology in the fourth quarter worth about $51,562,000. State Street Corp raised its position in shares of Vir Biotechnology by 18.9% in the 4th quarter. State Street Corp now owns 6,229,555 shares of the company’s stock worth $37,564,000 after acquiring an additional 988,262 shares in the last quarter. Orbimed Advisors LLC raised its position in shares of Vir Biotechnology by 5.9% in the 2nd quarter. Orbimed Advisors LLC now owns 2,380,715 shares of the company’s stock worth $11,999,000 after acquiring an additional 132,466 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Vir Biotechnology by 3.6% in the 4th quarter. Geode Capital Management LLC now owns 2,328,207 shares of the company’s stock valued at $14,041,000 after purchasing an additional 81,985 shares during the period. Finally, Goldman Sachs Group Inc. boosted its position in shares of Vir Biotechnology by 3.1% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,568,904 shares of the company’s stock valued at $9,460,000 after purchasing an additional 47,102 shares in the last quarter. Institutional investors own 65.32% of the company’s stock.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.